|
5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC |
|
|
|
Titel: |
5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC |
Auteur: |
Velcheti, Vamsidhar Rai, Pragya Kao, Yu-Han Chirovsky, Diana Nunes, Ana Tablante Liu, Stephen V. |
Verschenen in: |
Clinical lung cancer |
Paginering: |
Jaargang 25 () nr. 6 pagina's 502-508.e3 |
Jaar: |
2024 |
Inhoud: |
|
Uitgever: |
Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, The Author(s) |
Bronbestand: |
Elektronische Wetenschappelijke Tijdschriften |
|
|
|
|